reference/35799778

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/35799778

Outgoing Links

Predicate	Object
contentType	Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	535
issn	2168-6068
issueIdentifier	5
pageRange	526-535
publicationName	JAMA Dermatology
startingPage	526
bibliographicCitation	Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 01;159(5):526–35. PMID: 37043227; PMCID: PMC10099102.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3aa5739be0dfb0867c8d029dd5688a1a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3f0e03e469f691dc39a6b994f9d48ea5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_097b3c6670dd92211199c107f2ed0a89 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_185f8176118fbc45d0584521557df4f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_335da9ca86647b03e70c33dee257663a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff42947880566e753437cc70a84386f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab0514287ccde565dee98c1c037bb75f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59b6d4f7bfefa8df25956fc7bdfeb9b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad07b8d954cb2473bda665faf07ac215 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_08767b81cd61669b04a3e7f498ee58f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3f3d3780748362e7ed0cc392671169d6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63d67d3087a77cbb023a76680103346d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e42b54275927493d8580efaa46e9d831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6d2ea99dc5ccd636ac995383478428f8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d44ab9b0b37f65d348ec2ec54e8275d7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f60bd352c852c03727d0deef97f00262 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89d2cd84be28ac0b1cdc94b0a2a1ac9c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bcaa872eecc4be2b509764021793ed62 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf797fd00638e7b103fb59af73d5a715 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e180da32d706401ffc94c1088c0747c3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1e5f65a1db344cc6f023c532c2f57ed
date	2023-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1001/jamadermatol.2023.0391 https://pubmed.ncbi.nlm.nih.gov/37043227 https://pubmed.ncbi.nlm.nih.gov/PMC10099102
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/40862 https://portal.issn.org/resource/ISSN/2168-6068
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials
discusses	http://id.nlm.nih.gov/mesh/M000646360
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D003876Q000188 http://id.nlm.nih.gov/mesh/D004485
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D012720 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D011788
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7433 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58557659 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6777 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7547

Total number of triples: 55.